What is the recommended first‑line pharmacologic treatment and dosing for a medically stable patient with bulimia nervosa (purging type)?

First-Line Pharmacologic Treatment for Bulimia Nervosa (Purging Type)

Fluoxetine 60 mg daily is the only FDA-approved medication and the recommended first-line pharmacologic treatment for medically stable patients with bulimia nervosa, purging type. 1, 2

Dosing and Administration

• Start fluoxetine at 60 mg once daily, administered in the morning. 1, 2
• For patients who may not tolerate the full dose immediately, titrate up to the 60 mg target dose over several days. 2
• Do not use standard antidepressant doses of 20 mg daily—this dose is ineffective for bulimia nervosa. 1
• The maximum dose should not exceed 80 mg/day, though doses above 60 mg/day have not been systematically studied in bulimia nervosa. 2

Evidence Supporting This Recommendation

• Fluoxetine 60 mg daily is statistically superior to placebo in reducing both binge-eating and purging frequency. 1
• In controlled trials, only the 60 mg dose (not 20 mg) demonstrated significant superiority over placebo. 2
• The American Psychiatric Association designates fluoxetine as the primary pharmacologic agent with strong evidence and FDA approval specifically for bulimia nervosa. 1

Integration with Psychotherapy

• Initiate fluoxetine alongside cognitive-behavioral therapy (CBT) from the start, or add it if there is minimal or no response to psychotherapy alone by 6 weeks of treatment. 1
• CBT focused on eating disorders should continue throughout pharmacologic treatment to optimize outcomes. 1

Alternative Options for Fluoxetine Intolerance

If the patient cannot tolerate fluoxetine, consider alternative SSRIs based on moderate-quality evidence:

• Sertraline 100 mg daily for 12 weeks can reduce binge-eating and purging frequency. 1
• Citalopram may be particularly useful when prominent depressive symptoms coexist with bulimia nervosa. 1
• Fluvoxamine 200 mg daily has demonstrated efficacy in reducing binge-eating crises and purging episodes in randomized controlled trials. 3, 4

Pre-Treatment Safety Assessment

Before initiating any medication, obtain:

• Vital signs including orthostatic blood pressure (especially important in patients with severe purging). 1
• Complete blood count to assess for hematologic abnormalities. 1
• Comprehensive metabolic panel including electrolytes to detect purging-related imbalances. 1
• Electrocardiogram in patients with severe purging behaviors to assess for QTc prolongation. 1

Monitoring and Duration

• Assess treatment response every 6-12 weeks by quantifying reduction in binge-eating and purging frequency. 1
• Systematic evaluation demonstrates benefit of maintenance treatment with fluoxetine 60 mg/day for up to 52 weeks in patients who respond during acute treatment. 2
• Periodically reassess the need for continued treatment and adjust dosage to maintain the patient on the lowest effective dose. 2

Special Populations

• Hepatic impairment: Use a lower or less frequent dosage. 2
• Elderly patients: Consider lower or less frequent dosing. 2
• Concurrent medications or multiple comorbidities: Lower or less frequent dosing may be appropriate. 2
• Renal impairment: Dosage adjustments are not routinely necessary. 2

Common Pitfalls to Avoid

• Never prescribe fluoxetine 20 mg daily for bulimia nervosa—this standard antidepressant dose lacks efficacy for eating disorder symptoms. 1
• Do not delay medication initiation in patients who show poor response to psychotherapy alone by 6 weeks. 1
• Avoid using appetite stimulants approved for cancer-related anorexia (megestrol acetate, dexamethasone) in eating disorders, as the pathophysiology and treatment goals fundamentally differ. 1